David R. King

• Joined Quaker BioVentures as a Venture Partner in June 2008
• Previously: CEO and founder of BioRexis Pharmaceutical Corporation (acquired by Pfizer), President of Delsys Pharmaceutical Corporation (acquired by Elan), CEO of Principia Pharmaceutical (acquired by Human Genome Sciences). Prior to becoming a successful serial entrepreneurial, David was a partner at Morgan, Lewis & Bockius LLP, where he founded and was a leader of the venture capital and emerging business practice.
• Current Board Responsibilities: Xencor Inc. (Chairman), PA Bio
• Prior Board Participation: Cephalon, 3-Dimensional Pharmaceuticals (acquired by J&J), Morphotek (acquired by Eisai), Innovation Philadelphia, Ursinus College, Snider Entrepreneurial Center of the University of Pennsylvania’s Wharton School
• Education: J.D. from Harvard Law School and undergraduate studies at the University of Pennsylvania